CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2642 · Search date 2026-08-15 · Methodology v0.7

School YAM programme,
does it really help with Fewer suicide attempts over 12 months in adolescents?

30-Second Summary
C
Evidence Grade C · 56 · Safety caution
Reported suicide attempts fell at 12 months, but substantial exclusions and unblinded self-report remain
Suicide-related screening requires immediate risk assessment, referral pathways, and crisis procedures. YAM is not a substitute for acute treatment of a suicidal crisis.
What the
research shows
The grade is C with 56 points. In a 168-school cluster trial across ten European countries, 12-month self-reported suicide attempts were 14/1,987 (0.70%) with YAM versus 34/2,256 (1.51%) in controls, OR 0.45 (95% CI 0.24 to 0.85). The event difference was large, but the analyzed groups were substantially smaller than the 2,721 and 2,933 allocated pupils, and participants knew their programme while reporting their own attempts.
What the
ads claim
Results for a specific five-session package of role-play, lectures, booklets, and posters cannot be converted into proof for every school awareness lesson. Education also cannot replace clinical assessment and emergency referral for a pupil in crisis.
*

Useful facts when choosing a product

  • YAM is a five-session universal programme using student role-play, lectures, booklets, and classroom posters.
  • The 12-month analysis denominators were 1,987 YAM and 2,256 control pupils, distinct from randomized counts.
  • DRKS00000214 and NCT00906620 are linked country records of the same SEYLE trial, not two independent trials.
Gap Measurement · Verdict 2642 · C 56
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

SEYLE cluster-randomized 11,110 pupils in 168 schools to QPR 2,692, YAM 2,721, professional screening 2,764, or control 2,933. Schools were assigned by random-number generator. The primary outcome was suicide attempts by three and 12 months; the 12-month YAM-control comparison was 14/1,987 versus 34/2,256, OR 0.45 (95% CI 0.24 to 0.85; P=0.014). The EU Seventh Framework Programme funded the study and the paper declared no competing interests. DRKS00000214 is the main registration; NCT00906620 is a country-specific record for the Israeli site, not independent replication.

02

Why this is classified as C (56)

A large publicly funded cluster trial found fewer direct events, but substantial exclusions, unblinded self-report, and no independent replication give C with 56 points.

Counterpoint. This is universal school prevention and was not pooled with clinical CBT for high-risk patients after a recent attempt.

Rejudgment record. Cross-check applied — Cross-checked allocated and analyzed counts, baseline exclusions, self-reported outcomes, public funding, and registration against the Lancet report

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Fewer suicide attempts at 12 monthsCRates were 14/1,987 versus 34/2,256.
Fewer suicide attempts at three monthsDThere was no significant difference at three months.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Wasserman D, Hoven CW, Wasserman C, Wall M, Eisenberg R, Hadlaczky G, Kelleher I, Sarchiapone M, Apter A, Balazs J, Bobes J, Brunner R, Corcoran P, Cosman D, Guillemin F, Haring C, Iosue M, Kaess M, Kahn JP, Keeley H, Musa GJ, Nemes B, Postuvan V, Saiz P, Reiter-Theil S, Varnik A, Varnik P, Carli V. 2015 SEYLEMultinational cluster randomized controlled trial in 168 schools2,256Public EU Seventh Framework Programme funding; no competing interests declaredPrimary self-reported suicide attempts at three and 12 monthsAt 12 months, 14/1,987 (0.70%) versus 34/2,256 (1.51%), OR 0.45 (95% CI 0.24 to 0.85), P=0.014Only large direct cluster trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-15).

Wasserman D, Hoven CW, Wasserman C, Wall M, Eisenberg R, Hadlaczky G, Kelleher I, Sarchiapone M, Apter A, Balazs J, Bobes J, Brunner R, Corcoran P, Cosman D, Guillemin F, Haring C, Iosue M, Kaess M, Kahn JP, Keeley H, Musa GJ, Nemes B, Postuvan V, Saiz P, Reiter-Theil S, Varnik A, Varnik P, Carli V. School-based suicide prevention programmes: the SEYLE cluster-randomised, controlled trial. Lancet. 2015;385:1536-1544. PMID: 25579833. DOI: 10.1016/S0140-6736(14)61213-7. DRKS00000214.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

School YAM programme x prevention of adolescent suicide attempts Evidence Grade C card
[Chamgap] School YAM programme x prevention of adolescent suicide attempts — Evidence Grade C·56. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/youth-aware-mental-health-school-program-suicide-attempts/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.